Subutex 300 mg injektionsvätska

DRUG2 trials

Sponsors

Indivior Inc., Linkopings Universitet

Conditions

Opioid Use DisorderOpioid Use Disorder [OUD]

Phase 2

The dual orexin receptor antagonist daridorexant as an adjunct to improve buprenorphine maintenance therapy of opioid use disorder

RecruitingCTIS2024-517482-16-00

Linkopings UniversitetOpioid Use Disorder [OUD]

Start: 2025-04-04Target: 192Updated: 2025-05-26

Phase 4

A Phase IV Longitudinal Study of SUBLOCADE (SUBUTEX Prolonged Release) Clinical Outcomes in Adults with Opioid Use Disorder (Opioid Dependence)

CompletedCTIS2023-505098-34-00

Indivior Inc.Opioid Use Disorder

Start: 2024-04-22End: 2025-08-31Target: 50Updated: 2025-04-29